Have a personal or library account? Click to login
Is There Any Difference in Stem Cell Population between Type I and Type II Endometrial Cancer? A Pilot Study Cover

Is There Any Difference in Stem Cell Population between Type I and Type II Endometrial Cancer? A Pilot Study

Open Access
|May 2025

References

  1. Rodríguez-Palacios DÁ, Colorado-Yohar SM, Velten M, Vaamonde-Martín RJ, Ballesta M, Chirlaque MD. Incidence and trend of type I and II endometrial cancer in women from two population-based European cancer registries (1998–2012). Int J Environ Res Public Health. 2022 Mar 23;19(7):3789. doi: 10.3390/ijerph19073789.
  2. Gu B, Shang X, Yan M, Li X, Wang W, Wang Q, et al. Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990–2019. Gynecol Oncol. 2021 May;161(2):573–80. doi: 10.1016/j.ygyno.2021.01.036. Epub 2021 Feb 5.
  3. Aune D, Navarro Rosenblatt DA, Chan DS, Vingeliene S, Abar L, Vieira AR, et al. Anthropometric factors and endometrial cancer risk: a systematic review and dose-response meta-analysis of prospective studies. Ann Oncol. 2015 Aug;26(8):1635–48. doi: 10.1093/annonc/mdv142. Epub 2015 Mar 19.
  4. Kitson SJ, Crosbie EJ. Endometrial cancer and obesity. Obstet Gynaecol. 2019 Oct;21(4):237–45. doi: 10.1111/tog.12601. Epub 2019 Jul 25.
  5. Naqvi A, MacKintosh ML, Derbyshire AE, Tsakiroglou AM, Walker TDJ, McVey RJ, et al. The impact of obesity and bariatric surgery on the immune microenvironment of the endometrium. Int J Obes (Lond). 2022 Mar;46(3):605–612. doi: 10.1038/s41366-021-01027-6. Epub 2021 Dec 2.
  6. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983 Feb;15(1):10–7. doi: 10.1016/0090-8258(83)90111-7.
  7. Makker V, MacKay H, Ray-Coquard I, Levine DA, Westin SN, Aoki D, et al. Endometrial cancer. Nat Rev Dis Primers. 2021 Dec 9;7(1):88. doi: 10.1038/s41572-021-00324-8.
  8. Doll A, Abal M, Rigau M, Monge M, Gonzalez M, Demajo S, et al. Novel molecular profiles of endometrial cancer-new light through old windows. J Steroid Biochem Mol Biol. 2008 Feb;108(3–5):221–9. doi: 10.1016/j.jsbmb.2007.09.020. Epub 2007 Sep 15.
  9. Capp JP. Cancer stem cells: From historical roots to a new perspective. J Oncol. 2019 Jun 11;2019:5189232. doi: 10.1155/2019/5189232.
  10. Dieter SM, Ball CR, Hoffmann CM, Nowrouzi A, Herbst F, Zavidij O, et al. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell. 2011 Oct 4;9(4):357–65. doi: 10.1016/j.stem.2011.08.010.
  11. Walcher L, Kistenmacher AK, Suo H, Kitte R, Dluczek S, Strauß A, et al. Cancer stem cells-origins and biomarkers: Perspectives for targeted personalized therapies. Front Immunol. 2020 Aug 7;11:1280. doi: 10.3389/fimmu.2020.01280..
  12. Desai A, Yan Y, Gerson SL. Concise reviews: Cancer stem cell targeted therapies: Toward clinical success. Stem Cells Transl Med. 2019 Jan;8(1):75–81. doi: 10.1002/sctm.18-0123. Epub 2018 Oct 17.
  13. Yuan S, Norgard RJ, Stanger BZ. Cellular plasticity in cancer. Cancer Discov. 2019 Jul;9(7):837–851. doi: 10.1158/2159-8290.CD-19-0015. Epub 2019 Apr 16.
  14. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646–74. doi: 10.1016/j.cell.2011.02.013.
  15. Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res. 2006 May 1;66(9):4553–7. doi: 10.1158/0008-5472.CAN-05-3986. Erratum in: Cancer Res. 2006 Jun 15;66(12):6458.
  16. Ding DC, Liu HW, Chang YH, Chu TY. Expression of CD133 in endometrial cancer cells and its implications. J Cancer. 2017 Jul 15;8(11):2142–2153. doi: 10.7150/jca.18869.
  17. Sun Y, Yoshida T, Okabe M, Zhou K, Wang F, Soko C, et al. Isolation of stem-like cancer cells in primary endometrial cancer using cell surface markers CD133 and CXCR4. Transl Oncol. 2017 Dec;10(6):976–87. doi: 10.1016/j.tranon.2017.07.007. Epub 2017 Nov 2.
  18. Tomasetti C, Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science. 2015 Jan 2;347(6217):78–81. doi: 10.1126/science.1260825.
  19. Schoenhals M, Kassambara A, De Vos J, Hose D, Moreaux J, Klein B. Embryonic stem cell markers expression in cancers. Biochem Biophys Res Commun. 2009 May 29;383(2):157–62. doi: 10.1016/j.bbrc.2009.02.156. Epub 2009 Mar 4.
  20. Tamaki T, Shimizu T, Niki M, Shimizu M, Nishizawa T, Nomura S. Immunohistochemical analysis of NANOG expression and epithelial-mesenchymal transition in pulmonary sarcomatoid carcinoma. Oncol Lett. 2017 May;13(5):3695–702. doi: 10.3892/ol.2017.5864. Epub 2017 Mar 16.
  21. Clark DW, Palle K. Aldehyde dehydrogenases in cancer stem cells: potential as therapeutic targets. Ann Transl Med. 2016 Dec;4(24):518. doi: 10.21037/atm.2016.11.82.
  22. Bhattacharya R, Nicoloso M, Arvizo R, Wang E, Cortez A, Rossi S, et al. MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res. 2009 Dec 1;69(23):9090–5. doi: 10.1158/0008-5472.CAN-09-2552. Epub 2009 Nov 10.
  23. Buechel M, Dey A, Dwivedi SKD, Crim A, Ding K, Zhang R, et al. Inhibition of BMI1, a therapeutic approach in endometrial cancer. Mol Cancer Ther. 2018 Oct;17(10):2136–2143. doi: 10.1158/1535-7163.MCT-17-1192. Epub 2018 Jul 19.
  24. Gan L, Yang Y, Li Q, Feng Y, Liu T, Guo W. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomark Res. 2018 Mar 9;6:10. doi: 10.1186/s40364-018-0122-2.
  25. Tahara S, Nojima S, Ohshima K, Hori Y, Kurashige M, Wada N, et al. S100A4 accelerates the proliferation and invasion of endometrioid carcinoma and is associated with the “MELF” pattern. Cancer Sci. 2016 Sep;107(9):1345–52. doi: 10.1111/cas.12999. Epub 2016 Aug 12.
  26. Chen Y, Wang J, Wang D, Kang T, Du J, Yan Z, et al. TNNT1, negatively regulated by miR-873, promotes the progression of colorectal cancer. J Gene Med. 2020 Feb;22(2):e3152. doi: 10.1002/jgm.3152. Epub 2019 Dec 23.
  27. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature. 2013 Sep 19;501(7467):328–37. doi: 10.1038/nature12624.
  28. Castelli V, Giordano A, Benedetti E, Giansanti F, Quintiliani M, Cimini A, et al. The great escape: The power of cancer stem cells to evade programmed cell death. Cancers (Basel). 2021 Jan 17;13(2):328. doi: 10.3390/cancers13020328.
  29. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008 May 16;133(4):704–15. doi: 10.1016/j.cell.2008.03.027.
  30. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature. 2010 Dec 9;468(7325):824–8. doi: 10.1038/nature09557. Epub 2010 Nov 21. Erratum in: Nature. 2011 Jan 20;469(7330):432. Erratum in: Nature. 2011 Sep 8;477(7363):238.
  31. Ishiguro T, Ohata H, Sato A, Yamawaki K, Enomoto T, Okamoto K. Tumor-derived spheroids: Relevance to cancer stem cells and clinical applications. Cancer Sci. 2017 Mar;108(3):283–9. doi: 10.1111/cas.13155.
  32. Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, et al.; Cancer genome Atlas research network: Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell. 2018 Apr 5;173(2):338–354.e15. doi: 10.1016/j.cell.2018.03.034.
  33. Lau EY, Ho NP, Lee TK. Cancer stem cells and their microenvironment: Biology and therapeutic implications. Stem Cells Int. 2017;2017:3714190. doi: 10.1155/2017/3714190. Epub 2017 Feb 26.
  34. Monk M, Holding C. Human embryonic genes re-expressed in cancer cells. Oncogene. 2001 Dec 6;20(56):8085–91. doi: 10.1038/sj.onc.1205088.
  35. Zhao W, Li Y, Zhang X. Stemness-related markers in cancer. Cancer Transl Med. 2017;3(3):87–95. doi: 10.4103/ctm.ctm_69_16. Epub 2017 Jun 8.
  36. van der Zee M, Sacchetti A, Cansoy M, Joosten R, Teeuwssen M, Heijmans-Antonissen C, et al. IL6/JAK1/STAT3 signaling blockade in endometrial cancer affects the ALDHhi/CD126+ stem-like component and reduces tumor burden. Cancer Res. 2015 Sep 1;75(17):3608–22. doi: 10.1158/0008-5472.CAN-14-2498. Epub 2015 Jun 30. [cited 2023 Aug 24].
  37. Rahadiani N, Ikeda J, Mamat S, Matsuzaki S, Ueda Y, Umehara R, et al. Expression of aldehyde dehydrogenase 1 (ALDH1) in endometrioid adenocarcinoma and its clinical implications. Cancer Sci. 2011 Apr;102(4):903–8. doi: 10.1111/j.1349-7006.2011.01864.x. Epub 2011 Feb 9.
  38. Wen Y, Cai J, Hou Y, Huang Z, Wang Z. Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target. Oncotarget. 2017 Jun 6;8(23):37974–90. doi: 10.18632/oncotarget.16467.
DOI: https://doi.org/10.34763/jmotherandchild.20252901.d-24-00041 | Journal eISSN: 2719-535X | Journal ISSN: 2719-6488
Language: English
Page range: 10 - 19
Submitted on: Oct 22, 2024
Accepted on: Mar 7, 2025
Published on: May 24, 2025
Published by: Institute of Mother and Child
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2025 N Muthuraman, Anitha Thomas, Thomas Samuel Ram, KM Mohankumar, Premila Abraham, published by Institute of Mother and Child
This work is licensed under the Creative Commons Attribution 4.0 License.